Novo Nordisk's Loss Is Eli Lilly's Gain, And Vice Versa (NYSE:NVO)

Novo Nordisk A/S gains momentum with FDA approval for Wegovy and strategic pricing. Click for why Novo outshines Eli Lilly and Company (LLY) for long-term growth.